Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) saw an uptick in trading volume on Tuesday . 218,119 shares traded hands during mid-day trading, an increase of 233% from the previous session’s volume of 65,521 shares.The stock last traded at $6.4710 and had previously closed at $6.54.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings downgraded Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Anbio Biotechnology presently has an average rating of “Sell”.
Get Our Latest Report on Anbio Biotechnology
Anbio Biotechnology Stock Up 0.9%
About Anbio Biotechnology
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
Featured Stories
- Five stocks we like better than Anbio Biotechnology
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
- AI Is Making Cybersecurity Harder to Ignore—These 3 ETFs Offer a Broad Bet
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
